Back to top

Supernus Pharmaceuticals Inc. Enters Oversold Territory

Read MoreHide Full Article

Supernus Pharmaceuticals Inc.’s (SUPN - Free Report) share price has entered into oversold territory with an RSI value of 27.1. The Zacks Consensus Estimate on Supernus Pharmaceuticals Inc.’s earnings for the full year period has loss of 0.01 cents over the past two months to $-2.49 per share. Currently, Supernus Pharmaceuticals Inc. is a Zacks #2 Rank (“Buy”), suggesting that now might be a good time to get in on (SUPN - Free Report) after its recent drop.

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Supernus Pharmaceuticals, Inc. (SUPN) - free report >>

More from Zacks Tale of the Tape

You May Like